Cancer Drug Design and Discovery
The ultimate authoritative source of information on the design of new anticancer agents, written by some of the leaders in the field, Cancer Drug Design and Discovery covers a number of recent notable successes as well as discussions of especially promising new therapies. These advances have provided information on targets involved in specific cancers that will hopefully lead to effective medicines for at least some of the common solid tumors. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of cancer drug design.

More than simply a collection of chapters describing cancer drug chemistry and biology, this book also provides authoritative clinical perspectives on clinical trials and how they may be best structured to exploit molecular targeting and minimize failure. The biological and chemical reasons behind why drugs fail are extensively explored, and strategies for overcoming them and optimizing drug properties are discussed. Issues such as resistance and angiogenesis are emphasized, and there is overall a focus on small molecule approaches. Includes drugs under development in addition to those drugs currently available. Provides authoritative clinical perspective on trials of new anticancer agents. Presents drug discovery examples through the use of case histories in areas such as DNA repair, cell cycle inhibitors, HSP90 inhibition and kinase targets.

1136496411
Cancer Drug Design and Discovery
The ultimate authoritative source of information on the design of new anticancer agents, written by some of the leaders in the field, Cancer Drug Design and Discovery covers a number of recent notable successes as well as discussions of especially promising new therapies. These advances have provided information on targets involved in specific cancers that will hopefully lead to effective medicines for at least some of the common solid tumors. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of cancer drug design.

More than simply a collection of chapters describing cancer drug chemistry and biology, this book also provides authoritative clinical perspectives on clinical trials and how they may be best structured to exploit molecular targeting and minimize failure. The biological and chemical reasons behind why drugs fail are extensively explored, and strategies for overcoming them and optimizing drug properties are discussed. Issues such as resistance and angiogenesis are emphasized, and there is overall a focus on small molecule approaches. Includes drugs under development in addition to those drugs currently available. Provides authoritative clinical perspective on trials of new anticancer agents. Presents drug discovery examples through the use of case histories in areas such as DNA repair, cell cycle inhibitors, HSP90 inhibition and kinase targets.

129.95 In Stock
Cancer Drug Design and Discovery

Cancer Drug Design and Discovery

Cancer Drug Design and Discovery

Cancer Drug Design and Discovery

eBook

$129.95 

Available on Compatible NOOK devices, the free NOOK App and in My Digital Library.
WANT A NOOK?  Explore Now

Related collections and offers


Overview

The ultimate authoritative source of information on the design of new anticancer agents, written by some of the leaders in the field, Cancer Drug Design and Discovery covers a number of recent notable successes as well as discussions of especially promising new therapies. These advances have provided information on targets involved in specific cancers that will hopefully lead to effective medicines for at least some of the common solid tumors. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of cancer drug design.

More than simply a collection of chapters describing cancer drug chemistry and biology, this book also provides authoritative clinical perspectives on clinical trials and how they may be best structured to exploit molecular targeting and minimize failure. The biological and chemical reasons behind why drugs fail are extensively explored, and strategies for overcoming them and optimizing drug properties are discussed. Issues such as resistance and angiogenesis are emphasized, and there is overall a focus on small molecule approaches. Includes drugs under development in addition to those drugs currently available. Provides authoritative clinical perspective on trials of new anticancer agents. Presents drug discovery examples through the use of case histories in areas such as DNA repair, cell cycle inhibitors, HSP90 inhibition and kinase targets.


Product Details

ISBN-13: 9780123972286
Publisher: Elsevier Science & Technology Books
Publication date: 09/30/2013
Sold by: Barnes & Noble
Format: eBook
Pages: 640
File size: 11 MB
Note: This product may take a few minutes to download.

About the Author

Stephen Neidle is an Emeritus Professor of Chemical Biology at University College London, where he has also been the Director of Research in the School of Pharmacy. He has published over 500 primary papers and reviews and is a principal inventor on 14 patent filings. He has also written and edited several books on nucleic acids and anti-cancer drugs.

Table of Contents

Introduction - Stephen Neidle Foreword - Hilary Calvert Part I. Basic Principles and methodology Modern cancer drug discovery: integrating targets, technologies and treatments — Paul Workman andIan Collins Pharmacogenomics and personalised medicines in cancer treatment — Wei-Peng Yong, Ross Soo andFederico Innocenti Structural biology and anticancer drug design — Puja Pathuri, David Norton, Henriette Willems,Dominic Tisi and Harren Jhoti Part II. Drugs in the laboratory and clinic Temozolomide: from cytotoxic to molecularly-targeted agent — Malcolm Stevens Temozolomide: patents and the perils of invention — Malcolm Stevens A new generation of cell-targeted drugs for cancer treatment — Paola B. Arimondo, Nicolas Guilbaudand Christian Bailly Inhibition of DNA repair as a therapeutic target — Stephany Veuger and Nicola J CurtinInhibitors of tumour angiogenesis — Adrian L. Harris and Daniele G Generali The Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer — Qingzhong Hu and RolfW. Hartmann Apoptosis in Cancer: Mechanisms, Deregulation and Therapeutic Targeting — Zahid H Siddik Targeting the MDM2-p53 protein-protein interaction: design, discovery and development of novelanticancer agents — Ian R Hardcastle Targeting altered metabolism – emerging cancer therapeutic strategy — Minsuh Seo, Robert BlakeCrochet and Yong-Hwan Lee Inhibitors of the Phosphatidylinositol 3-kinase (PI3K) Pathway — William A Denny and Gordon W.Rewcastle Antibody-drug conjugates delivering DNA cytotoxics — John A Hartley Inhibition of telomerase: promise, progress and potential pitfalls — Christopher G. Tomlinson, Scott B.Cohen and Tracy M. Bryan Targeting B-RAF: the discovery and development of B-RAF inhibitors — Phillip A Harris Part III. The reality of cancer drugs in the clinic Failure Modes in Anticancer Drug Discovery and Development — Richard A. Walgren andChristopher. A. Slapak Anticancer drug registration and regulation: current challenges and possible solutions — DavidTaylor, Erling Donnelly and Silvia Chioato

What People are Saying About This

From the Publisher

The second edition of this authoritative reference features the latest on the design and development of new anticancer small molecules, including topics such as the identification of molecular targets, cancer genomics, personalized medicine and more.

From the B&N Reads Blog

Customer Reviews